Dana-Farber Cancer Institute: Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 21 Leukemia, Lymphocytic, Chronic, B-Cell studies with Dana-Farber Cancer Institute as lead sponsor. 6 are open to participants now and 8 have results posted.

Phase 1 12Phase 2 8Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingNCT07847957Phase 1/2
• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
• Zanubrutinib and Venetoclax in CLL (ZANU-VEN)RecruitingNCT05168930Phase 2
• Understanding Chronic Lymphocytic LeukemiaRecruitingNCT04028531
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• Establishing a Tumor Bank in Families With Multiple Lymphoproliferative MalignanciesRecruitingNCT00131014
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSActive, not recruitingNCT03534323Phase 1/2Results posted
• A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaActive, not recruitingNCT02537613Phase 1Results posted
• A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedNCT02268851Phase 1Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedNCT02135133Phase 2Results posted
• Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01066663Phase 1/2Results posted
• Cardiotoxicities in Patients Receiving BTKiWithdrawnNCT05521178
• Safe Accelerated Venetoclax Escalation in CLLActive, not recruitingNCT04843904Phase 1
• ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
• Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLLTerminatedNCT00543114Phase 1
• Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationCompletedNCT00442130Phase 1
• Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine GenerationCompletedNCT00428233Phase 1
• Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLLCompletedNCT00330252Phase 1